The short-term effects of 0.25-mg brotizolam were compared with those of 30-mg flurazepam and placebo in 12 male heavy snorers with mild forms of obstructive sleep apnea syndrome (OSAS), in a randomized, double-blind trial according to a latin square design. Three polysomnographic all-night recordings were evaluated for each patient. Polysomnography included standard parameters, ear oximetry, and monitoring of body position. Among the parameters tested, the mean arterial oxygen saturation (SaO2), the lowest SaO2, the mean low SaO2, and the respiratory disturbances index (RDI, number of events with O2 desaturation of more than 4% per hour of sleep) during the night were evaluated. Concerning sleep parameters, brotizolam had no significant effect, while flurazepam significantly increased total sleep time (P <0.05) and tended to reduce wakefulness after sleep onset and number of awakenings. Concerning respiratory parameters, the RDI and the percentage of O2 saturation had no significant change with either drug with respect to placebo, although for some parameters there was a trend toward a reduction with brotizolam. According to our data, short-term administration of 0.25-mg brotizolam and 30-mg flurazepam does not significantly affect respiratory events or O2 saturation during the night in patients with mild forms of OSAS.
|Number of pages||7|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1992|
ASJC Scopus subject areas